MetaVia announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, has… read more.
Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to… read more.
The number of metabolic and bariatric surgery procedures in the United States dropped below 200,000 in 2024 for the first time since 2020, a more than 20% decline… read more.
Viking Therapeutics announced that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15,… read more.
Researchers report that weight-loss surgery improves outcomes for patients with obesity and chronic kidney disease by significantly reducing the risk of kidney failure, major cardiovascular events and death…. read more.
A new meta-analysis of relevant clinical studies suggests that GLP 1 weight-loss drugs provide protection against heart attacks, strokes and premature death for up to 2.7 years. The… read more.
Galderma issued new data from two investigator-initiated trials (IITs), demonstrating the power of Sculptra – the first proven regenerative biostimulator – and the company’s versatile hyaluronic acid injectable… read more.
A healthy diet, weight loss, and increased physical activity can effectively prevent type 2 diabetes. However, not all individuals at elevated diabetes risk benefit equally from lifestyle interventions…. read more.
A routine component of many medical appointments—stepping on the scale to be weighed—may be a stigmatizing experience that raises patients’ blood pressure and potentially impacts their healthcare, according… read more.
Researchers at Toronto’s Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a… read more.
Novo Nordisk presents the ORION study at the Obesity Medicine Association’s annual conference in San Diego showing that Wegovy (semaglutide) tablets 25 mg was associated with significantly greater… read more.
The European Medicines Agency (EMA) has approved an update to the product information for Wegovy injection that allows the medicine to stay at a controlled temperature of up… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
